Tomorrow.Mobility Shines Light on the New Driving Forces for More Liveable and Sustainable Cities
17.11.2022 17:38:00 EET | Business Wire | Press release
(15-17 November 2022) – Tomorrow.Mobility World Congress (TMWC) is a global event, co-organised by Fira de Barcelona and EIT Urban Mobility, in the Gran Via venue of Fira de Barcelona, focused on promoting the design and adoption of new sustainable urban mobility models and jointly organised with the Smart City Expo World Congress.
Over 80 speakers such as Kelly Larson, director of the Road Safety Programme at Bloomberg Philanthropies; Karen Vancluysen, secretary general of POLIS; Marco te Brömmelstroet, professor of Future of Urban Mobility at the University of Amsterdam; Mikael Colville-Andersen, Urban Design Expert and Maria Tsavachidis, CEO of EIT Urban Mobility, participated in the more than 20 congress and talks in Tomorrow.Mobility. EIT urban Mobility, an initiative of the European Institute of Innovation and Technology (EIT), a body of the European Union, sponsored the venue of more than 20 innovative startups. At this edition, two studies produced by EIT Urban Mobility are unveiled. FULL STUDY & Press Summary in the google drive.
The 15-minute city
The 15-minute city, is a recent concept that has taken momentum in wake of the pandemic and has been picked up by many European cities. The goal is to create a city where people could reach all their basic essential social functions like living, working, commerce, healthcare, education, and entertainment at a 15-minute by walk. In Europe, more than €1bn in cycling-related infrastructure and 2,300 kilometers of new bike lanes have been spent since the pandemic began.
Three workshops were conducted with planning practitioners from the metropolitan region of Amsterdam, Ghent, Madrid, Milan, and Munich. A key output of this study is a roadmap for the implementation of ±15-minute city strategies to ensure access all citizen’s needs, and in connection with suburb areas. 15-Minute City concepts need to be adapted to local circumstances and population groups: older people walking speed is on average around 3.5 km/h while the average speed is considered 5km/h. Hence, a 15-minute walk could represent 900-1000m at an average speed, while at a reduced speed it could be 700m.
Urban Air Mobility
Given the fast pace of innovation, air mobility is expected to become a reality in Europe within 3-5 years and air space above cities could become an extension of public space on the ground. The European UAM market size is predicted to be 4.2 billion EUR by 2030, representing a 31% global share1. To set up the scenes for an inclusive urban air mobility scheme, this first study explores the different evolution perspectives of the sector. The study collected practitioners’ insights on the development and implementation of UAM from 12 European countries from the academic, public, and private sector.
Out of the sectorial experts, 89% expect that UAM applications will play a very important or important role in improving medical transport and support in medical emergency services. 63% of questionnaire respondents think that in the logistics field, UAM will play an important or a very important role in the transport of packages in industrial spaces. By contrast, only a minority of experts see a significant role in UAM applications in e-commerce and food deliveries. In terms of challenge, when moving forward with UAM, it is essential to consult citizens and it´s important for them to feel safe, where subjective safety matters as much as objective ones. Traffic noise is the second main concern raised by the study, after safety, for the development of Urban Air Mobility for European citizens.
About EIT Urban Mobility
EIT Urban Mobility, an initiative of the European Institute of Innovation and Technology (EIT), a body of the European Union, aims to accelerate solutions and the transition towards a user-centric, integrated and truly multimodal transport system. As the leading European innovation community for urban mobility, EIT Urban Mobility works to avoid fragmentation by facilitating collaboration between cities, industry, academia, research and innovation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005677/en/
Contact information
Press Contact Details:
Marine Moulin ‐ E:
media@eiturbanmobility.eu ‐ M: +34 654 017 463
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom